BCL2 and breast carcinoma: The product of lipoxygenase-12, 12-hydroxy eicosatetraenoic acid (12-HETE) displayed mitogenic properties in breast cancer cells and its blockade by inhibitors resulted in downregulation of Bcl2, release of cytochrome c and activation of caspases [32].